Stay updated on Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial

Sign up to get notified when there's something new on the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    The page’s revision/version indicator was updated from **v3.5.2** to **v3.5.3**, reflecting a site or interface release rather than substantive trial-record changes.
    Difference
    0.1%
    Check dated 2026-04-24T22:26:09.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    Added revision v3.5.2 and removed revision v3.5.0 from the study record history.
    Difference
    0.1%
    Check dated 2026-04-17T14:17:48.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    A new revision entry v3.5.0 has been added and the previous entry v3.4.3 has been removed.
    Difference
    0.1%
    Check dated 2026-03-19T23:29:56.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    Added revision v3.4.3 and removed revision v3.4.2 in the record history.
    Difference
    0.1%
    Check dated 2026-03-12T18:38:51.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    The new screenshot shows a visual/UI refresh while the version history details remain the same; no substantive changes to study records are evident.
    Difference
    0.1%
    Check dated 2026-02-26T15:22:04.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    Record History now includes Revision: v3.4.2 and removes Revision: v3.4.1.
    Difference
    0.1%
    Check dated 2026-02-12T02:19:29.000Z thumbnail image

Stay in the know with updates to Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page.